Mark Mossler
CIK: 0001992219
Transaction Breakdown
Open Market Buys (P)0 (0.0%)
High conviction signal
Open Market Sales (S)0 (0.0%)
Position reduction
Option Exercises (M)1 (25.0%)
Derivative conversions
Awards (A)1 (25.0%)
Compensation grants
Other (G, F, J, C, D, …)2 (50.0%)
Gifts, tax withholding, conversions, dispositions to the issuer and other codes
Companies & Roles (1)
CCCC
C4 Therapeutics, Inc.
Officer
Discretionary Trading P&L
Holdings
Transaction History (4 total)
- Feb 14, 2026CCCC
C4 Therapeutics, Inc.
Exercise(M)Direct9.4K shares- - Feb 14, 2026CCCC
C4 Therapeutics, Inc.
Tax Payment(F)Direct3.3K shares at avg. $1.89$6K - Feb 13, 2026CCCC
C4 Therapeutics, Inc.
Award(A)Direct57K shares- - Feb 14, 2025CCCC
C4 Therapeutics, Inc.
Tax Payment(F)Direct1.6K shares at avg. $3.18$5K
1-4 of 4 transactions
About Mossler Mark
Mossler Mark (SEC CIK 0001992219) files insider reports with the SEC as Chief Accounting Officer of C4 Therapeutics, Inc. (CCCC).
Signal8 holds 2 ownership filings by Mossler Mark, all Form 4s, filed between Feb 18, 2025 and Feb 18, 2026. Those filings report 4 transactions, from Feb 14, 2025 to Feb 14, 2026. Signal8's Form 4 history starts in Sep 2024.
The business address on Mossler Mark's filings is in WATERTOWN, MA.
Recent filings by Mossler Mark
Other insiders filing for C4 Therapeutics, Inc. (CCCC)
- Anderson Kenneth Carl, Director
- GROGAN DONNA ROY, Director
- Adams Kendra, Chief Financial Officer
- REYNO LEONARD, Chief Medical Officer
- Hughes Owen, Director
- Hoerter Steven L., Director